Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Many Drug Approval Delays, Denials Could Be Prevented, FDA Study Shows

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency reports preventable deficiencies, including failure to select optimal drug doses and suitable study endpoints, account for many drug rejections, approval delays.

You may also be interested in...



Why Drugs Get Delayed: Blame It On Safety Concerns, Researchers Say

However, FDA allows manufacturers more leeway in providing additional data or new analyses to better understand a safety issue than an efficacy concern, according to a Health Affairs study of novel drugs approved after multi-cycle reviews.

FDA’s Top Two Reform Priorities Aren’t Really Legislative Material

Senate eyes a biomedical reform process that is simultaneously narrower and slower than the House’s 21st Century Cures Initiative; FDA’s Hamburg asks for ability to shape sponsor’s trial designs earlier and more regulatory science funding.

Mandatory FDA Review Of Pivotal Trial Protocols Urged In JAMA

Dartmouth researchers say that although FDA recommendations can strengthen study designs and improve outcome measures, sponsors often don’t follow agency’s advice or don’t even seek input in Phase III design.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS076407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel